argenx to acquire Forte Biosciences for $2.2bn
Dutch-Belgian immunology group argenx SE has entered a definitive agreement to acquire US-based biopharma group Forte Biosciences in an all-cash transaction valued at approximately $2.2bn. This deal, the largest in the history of the Euronext-listed firm, marks a significant pivot as argenx seeks to diversify its portfolio beyond its flagship blockbuster treatment, Vyvgart. Under the terms of the agreement, argenx…